Analysis of medical risk factors and outcomes in patients undergoing open versus endovascular abdominal aortic aneurysm repair  by Ligush, John et al.
Analysis of medical risk factors and outcomes in
patients undergoing open versus endovascular
abdominal aortic aneurysm repair
John Ligush, Jr, MD, Jeffrey D. Pearce, MD, Matthew S. Edwards, MD, Matthew R. Eskridge, BS,
Gregory S. Cherr, MD, George W. Plonk, MD, and Kimberley J. Hansen, MD, Winston-Salem, NC
Objective: The emergence of endovascular repair (ER) for infrarenal abdominal aortic aneurysm (AAA) has provided
surgeons with a new technique that should ideally improve patient outcomes. To more accurately characterize the
advantages of ER versus traditional/open AAA repair (TOR), we compared the preoperative medical risk factors
(PMRFs) and perioperative outcomes (PO) of those patients undergoing elective treatment of infrarenal AAA with ER
and TOR over a recent 18-month period at our center.
Methods: Through our institutional vascular surgery patient registry, all patients undergoing aortic aneurysm repair
of any type between December 1999 and June 2001 were identified. Only those patients undergoing elective
infrarenal AAA repair were analyzed. Hospital records were examined for all patients, and PMRF and PO were
assessed via Society for Vascular Surgery/International Society for Cardiovascular Surgery reporting guidelines.
Student t, 2, Fisher exact, or Wilcoxon rank sum tests were applied where appropriate to determine differences
among PMRF and PO according to method of aneurysm repair.
Results: During the 18-month study period, a total of 199 aortic aneurysms were repaired at our institution. Ninety-nine
elective infrarenal AAA repairs made up the study cohort (ER, n  33; TOR, n  66). When examined by method of
aneurysm repair, no differences existed in demographics or AAA size. Patients undergoing ER had a significantly greater
degree of preoperative pulmonary comorbidity than patients undergoing TOR (P < .001). However, no differences
existed in terms of American Society of Anesthesiologists classification or cardiac (P  .52), cerebrovascular (P  .44),
diabetic (P  .51), hypertensive (P  .90), hyperlipidemia (P  .91) or renal (P  .23) comorbidities between the two
groups. Perioperative morbidity and mortality rates were also not significantly different by method of repair. ER was
associated with shorter operative time, intensive care unit stay, and overall hospital length of stay (P < .0001). However,
subsequent operative procedures related to the AAA repair were performed more frequently after ER (TOR 1.5% versus
ER  15.2%; P  0.015).
Conclusion: These results suggest that ER offers improvements in hospital convalescent and operating room times
but no beneficial impact on overall morbidity and mortality rates when similar PMRFs exist, especially when used at
medical centers where low morbidity and mortality rates are already established for TOR. Other centers performing
ER should undertake such an analysis to assess its impact on their patients. (J Vasc Surg 2002;36:492-9.)
The development of catheter-based approaches for the
treatment of vascular disease continues to evolve and find
its place in the vascular surgeon’s armamentarium, but no
technique has revolutionized this burgeoning field like the
advent of endovascular repair (ER) of infrarenal abdominal
aortic aneurysm (AAA). ER offers several potential advan-
tages over traditional/open AAA repair (TOR), including
decreased operative time, lower blood loss, shorter hospital
stay, rapid recovery, lower intensive care unit (ICU) utili-
zation, and a lower surgical stress response.1-3 However, as
reports of late rupture, persistent endotension, graft limb
failure, graft migration, and other late complications re-
lated to ER appear in the literature,4-10 the once unbridled
enthusiasm for ER has turned to cautious optimism.11-14
The uncertainty of these increasingly reported unto-
ward events has lead to cautionary recommendations re-
garding the limitation of ER to the patient at high
risk.11,13-16 However, because no randomized prospective
trials comparing ER with TOR were conducted during the
early evaluation of this new technology, meaningful data
regarding risk stratification or the impact of ER in improv-
ing outcome relative to TOR at varying levels of risk have
yet to be published. Thus, the definition of “high risk”
remains nebulous at best, and as a result, the population
most likely to benefit from ER can be inferred but not
completely defined. At this point, therefore, it is not clear
that the potential short-term superiority of ER justifies the
abandonment of the well-established long-term durability
conveyed by TOR or that ER is superior to TOR with
regards to perioperative morbidity and mortality at equiv-
alent levels of preoperative risk. With these points in mind,
we compared the preoperative medical risk factors and
perioperative outcomes of patients undergoing elective
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treatment of infrarenal AAA repair with ER or TOR during
a recent 18-month period at our institution to assess the
potential advantages of ER compared with TOR.
PATIENTS AND METHODS
Study design. This clinical investigation was under-
taken to compare the preoperative medical risk factors and
perioperative outcomes of patients undergoing elective ER
or TOR for infrarenal AAA at our institution. Approval for
this project was obtained from the institutional review
board for human subjects research at the Wake Forest
University School of Medicine. A retrospective assessment
of the preoperative medical risk factors and perioperative
outcomes was performed for each patient and statistically
analyzed to determine differences between the two treat-
ment groups with regard to these clinical endpoints.
Patient population. Patients undergoing operative
repair of an aortic aneurysm during the 18-month period
between December 1999 and June 2001 were identified
through our institutional vascular surgery patient registry.
Patients undergoing repair of thoracoabdominal, suprare-
nal, pararenal, ruptured, or symptomatic aortic aneurysms,
and patients undergoing aortic aneurysm repair with com-
bined visceral or renal artery reconstructions, were ex-
cluded from further consideration. Only patients undergo-
ing elective infrarenal AAA repair were considered for this
study. These remaining patients were classified according
to the method of aneurysm repair: ER or TOR. The selec-
tion criteria for ER were based on recommended anatomic
criteria for aortic stent graft placement (Medtronic AVE,
Santa Rosa, Calif) in conjunction with apparent increased
medical risk for TOR or patient preference after a detailed
risk/benefit explanation to the patient. The two patient
cohorts were not retrospectively analyzed to determine
whether all patients were candidates for ER. Medical
records were reviewed for all patients in the study cohort.
Clinical endpoints. Using established reporting stan-
dards,17 we abstracted data that included demographics,
preoperative medical comorbidities, and American Society
of Anesthesiologists (ASA) classification18 from the hospi-
tal record. Aneurysm size and extent were determined on
the basis of dimensions obtained from abdominal com-
puted tomography (CT), ultrasound scanning, and the
operative record. Postoperative complications were re-
corded according to recommended standards.17 Only ma-
jor postoperative morbidity leading to increased hospital
stay, need for reoperative therapy, permanent disability, or
death was considered in the statistical analysis. Perioperative
mortality was defined as all deaths within 30 days of oper-
ation or within the same hospitalization regardless of inter-
val.
Operative treatment. All ERs were performed in the
operating room with spinal, epidural, local, or general
anesthesia via bilateral groin cut-down. AneuRx grafts
(Medtronic AVE) were used for ER in all cases. Proximal or
distal extension endoprostheses were placed as needed to
assure complete AAA exclusion.
All TORs were performed in the operating room in a
standard fashion via transabdominal or retroperitoneal ap-
proaches with general or general plus epidural anesthesia
with knitted Dacron prostheses. Concurrent iliac aneurysm
repair was performed as deemed necessary by the operating
surgeon.
Statistical analysis. All statistical analyses were per-
formed with the Statistical Analysis Software, version eight
(SAS Institute, Cary, North Carolina). Dichotomous data
(demographics, morbidity, and mortality) were analyzed
according to the method of aneurysm repair with 2 or
Fisher exact tests. All continuous variables were analyzed
with Student t test. Graded medical comorbidity and ASA
classification data were analyzed with the nonparametric
Wilcoxon rank sum test to take into account both the
frequency and the severity of the condition/measure. All
statistical tests were considered significant when the P value
was less than .05.
RESULTS
Patient characteristics. During the 18-month study
period, 199 aortic aneurysm repairs were performed at our
institution. Of the 199 repairs, 13 thoracoabdominal, 11
pararenal, and 52 ruptured or symptomatic aneurysms and
24 aneurysms with visceral/renal reconstruction were ex-
cluded from further analyses. The study cohort was com-
prised of the remaining 99 patients (33 ER and 66 TOR)
undergoing elective infrarenal AAA repair.
None of the patients undergoing TOR needed supra-
renal clamping during the AAA repair. Iliac aneurysms that
needed concomitant repair during TOR were present in 26
of 66 patients (39%). Four of these 26 patients needed
more extensive bypass for occlusive disease. In the ER
group, 13 of 33 patients (39%) had iliac aneurysms that
needed treatment. Ten bilateral and three unilateral exten-
sion endoprostheses were necessary for treatment of the
iliac aneurysms. Two patients undergoing ER needed con-
comitant iliac angioplasty and stenting for occlusive disease,
including one recanalization of a totally occluded iliac
artery.
Demographics for the study cohort are summarized in
Table I. The mean age was 70.4  7.5 years, 88% of
patients were male, and 97% of patients were white. The
mean aneurysm size was 5.6 1.1 cm. When examined by
method of operative repair, no significant differences were
found among demographic factors or aneurysm size.
Preoperative medical comorbidities and operative
risk factors. Preoperative medical comorbidity and ASA
classification data are presented in Table II. When exam-
ined by method of AAA repair, the only significant differ-
ence that existed between the two groups was in the higher
degree of pulmonary disease in the ER group (P  .001).
No significant differences existed in terms of the other
considered medical preoperative comorbidities or ASA clas-
sification.
Perioperative results. Anesthesia and operative time
data are presented in Table III. All patients undergoing
TOR were administered a general anesthetic compared
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with only two patients (6%) undergoing ER (P  .001).
Operative time was significantly shorter for ER (177 min-
utes versus 277 minutes; P  .001).
Perioperative outcome data are presented in Table IV.
Patients undergoing ER showed both shorter ICU (P 
.001) and overall hospital (P .001) stays. Patients under-
going ER were significantly more likely to need subsequent
operative procedures related to their aneurysm repair (15%
versus 1.5%; P  .015). In the ER group, two of the
subsequent procedures were related to the treatment of
type I endoleaks. One was detected on postoperative day 1
with duplex scan and was treated with a proximal aortic cuff
Table I. Patient characteristics
Variable All patients (n  99) Open repairs (n  66) Endovascular repairs (n  33) P value
Age (y) 70.4  7.5 69.7  7.6 71.9  7.2 .17
Male gender 87 (88%) 58 (88%) 29 (88%) 1.00
Race .31
White 97 (98%) 64 (97%) 33 (100%) –
African American 2 (2%) 2 (3%) 0 (0) –
Weight (kg) 81.4  16.5 81.1  17.7 82.0  14.0 .80
Aneurysm size (cm) 5.6  1.1 5.8  1.2 5.4  0.6 .06
Table II. Preoperative medical risk factors
Risk factor* All patients (n  99) Open repairs (n  66) Endovascular repairs (n  33) P value
Coronary artery disease 62 (63%) 44 (67%) 18 (55%) .521
Cerebrovascular disease 14 (14%) 8 (12%) 6 (18%) .445
Pulmonary disease 47 (48%) 24 (36%) 23 (70%) .001
Renal insufficiency 22 (22%) 12 (18%) 10 (30%) .234
Lower extremity ischemia 14 (14%) 10 (15%) 4 (12%) .682
Diabetes mellitus 20 (20%) 12 (18%) 8 (24%) .542
Hypertension 76 (77%) 51 (77%) 25 (76%) .902
Smoking 87 (88%) 58 (88%) 29 (88%) .182
Hypercholesterolemia 54 (55%) 36 (55%) 18 (55%) .911
ASA classification .451
II 8 (8%) 4 (6%) 4 (12%) –
III 71 (72%) 48 (73%) 23 (70%) –
IV 20 (20%) 14 (21%) 6 (18%) –
*Classified according to Society for Vascular Surgery/International Society for Cardiovascular Surgery guidelines.
Table III. Operative variables
Variable All patients (n  99) Open repairs (n  66) Endovascular repairs (n  33) P value
Anesthesia .001*
General 68 (69%) 66 (100%) 2 (6%) –
Epidural 13 (13%) – 13 (39%) –
Spinal 16 (16%) – 16 (49%) –
Local 2 (2%) – 2 (6%) –
Operative time (min) 243  86 277  82 177  45 .001
*Comparison of general versus nongeneral anesthetics with Pearson 2 test.
Table IV. Perioperative outcomes
Variable All patients (n  99) Open repairs (n  66) Endovascular repairs (n  33) P value
Operative time (min)* 243  86 277  82 177  45 .001
ICU stay (d)* 2.2  3.2 3.2  3.5 0.2  0.5 .001
Duration of ventilator use (d)* 0.9  5.7 1.3  6.9 0.1  0.2 .154
Significant morbidity rate 23 (23%) 13 (20%) 10 (30%) .239
Subsequent procedures 6 (6%) 1 (1.5%) 5 (15%) .015
Hospital length of stay (d)* 7.8  10.7 10.7  12.0 2.1  2.5 .001
Mortality rate 4 (4%) 1 (1.5%) 3 (9%) .107
*Mean  SD.
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extension that day. The other was treated within the 30-day
perioperative period with bilateral iliac extension prostheses
in the same patient. The three other operative procedures in
the ER group were related to operative drainage and debride-
ment of groin wound infections within the 30-day periopera-
tive period. In the TOR group, one patient needed explor-
atory laparotomy on postoperative day 1 for intraabdominal
hemorrhage. The rate of significant perioperative morbidity
trended higher for patients undergoing ER (30% versus 20%;
P .239), but this difference was not statistically significant.
Perioperative morbidity rate by method of repair is
detailed in Table V. The distribution of morbidity was
similar between the two groups, with the exception of a
trend towards more wound complications in the ER group
(P  .079). Cardiac complications were rare in both
groups, and in all cases were related to dysrhythmia (ER,
n 2; TOR, n 6). No myocardial infarctions occurred in
either group during the period under investigation. Peri-
operative mortality rate also trended higher in the ER
group but did not achieve statistical significance (9.1%
versus 1.5%; P .107). Among the deaths in the ER group,
two were caused by sudden cardiac death (one autopsy
proven; one presumed) after discharge from the hospital.
One occurred on postoperative day 2 in a patient undergo-
ing an uneventful ER, and the other on postoperative day
13. The third was caused by a hemorrhagic stroke and
secondary herniation (CT proven). None of the patients
had clinical evidence of AAA rupture or intraabdominal
hemorrhage at the time of death. The lone death in the
TOR group was caused by a gastrointestinal hemorrhage
occurring 60 days after surgery in our rehabilitation facility.
DISCUSSION
The emergence of ER has provided surgeons with a
new technique that should ideally improve patient out-
comes. However, in our series, with the exception of higher
preoperative pulmonary comorbidity, patients undergoing
ER and TOR showed similar preoperative medical risk
factor profiles and had similar rates of morbidity and mor-
tality after aneurysm repair. And none of the deaths in the
ER group could be attributed to the higher degree of
pulmonary comorbidity. Although the rates of both signif-
icant perioperative morbidity and mortality trended higher
among patients treated with ER, these differences did not
achieve statistical significance. ER was associated with de-
creases in ICU utilization, operative time, and hospital
length of stay. These results suggest that ER shortened
operative times and hospital convalescence but did not have
a beneficial effect on perioperative morbidity or mortality.
The therapeutic goal of AAA surgery is to decrease the
risk of aneurysm rupture and extend life. The balance
between the risk of AAA rupture and the risk of surgical
intervention has been extensively investigated and shown
to be intimately associated with the expertise of the centers
providing care for patients with AAA.19-21 The morbidity
rate associated with TOR has been reported to range from
15% to 30%, with mortality rate ranging from 2% to near
6%.19,20,22-24
ER appears to be an attractive alternative to TOR from
the standpoint of its potential for less morbidity and more
rapid patient recovery. Several centers with large endovas-
cular experience have reported advantages of ER over
TOR, including decreased operative time, lower blood loss,
shorter hospital stay, lower ICU utilization, and a lower
surgical stress response.1-3 However, reports of late AAA
rupture, graft migration, limb kinking and thrombosis,
endotension, and endoleak have continued to surface in the
literature,4-10 leading to a dampening of the once unbri-
dled enthusiasm for ER. Several publications have at-
tempted to explain these shortcomings,5,25 and one recent
editorial has basically condemned ER altogether.26
Our center cares for a large number of patients with
complex aortic pathology, as is evidenced by the distribu-
tion of aneurysm disease reported herein. Of the 199
aneurysm repairs performed at our institution over an 18-
month period, only 99 of these were for infrarenal AAA.
This volume of experience has resulted in considerable
expertise in the open management of aneurysms, with a
30-day mortality rate for elective TOR of 1.2% over the
past 10 years. This low level of mortality sets a high stan-
dard for any alternative methods of aneurysm repair. In our
opinion, an alternative therapy for AAA would have to
impact even our highest risk patients significantly from the
standpoint of mortality and morbidity to make its applica-
tion justifiable.
Although we firmly believed that patients receiving ER
had more significant preoperative medical risk factors than
those undergoing TOR at our institution, the data do not
bear that out. Indeed, the preoperative medical risk factors
in those patients undergoing either TOR or ER were
similar in almost all respects, with the exception of preop-
erative pulmonary comorbidity. Furthermore, none of the
deaths in our ER group could be attributed to pulmonary
complications. These findings are in keeping with other
published reports. Zarins et al1 reported on a large prospec-
tive, nonrandomized, multicenter experience of ER versus
TOR and found similar preoperative medical risk factors for
both treatment arms, even though the TOR group was
enrolled first. Given the fact that overall preoperative med-
ical risk factors were not significantly different in our treat-











Cardiac 8 (8%) 6 (9%) 2 (6%) .715
Pulmonary 4 (4%) 3 (5%) 1 (3%) 1.000
Stroke 3 (3%) 2 (3%) 1 (3%) 1.000
Thromboembolic 4 (4%) 2 (3%) 2 (6%) .599
Gastrointestinal 2 (2%) 2 (3%) 0 (0) .551
Genitourinary 2 (2%) 2 (3%) 0 (0) .551
Wound 10 (10%) 4 (6%) 6 (18%) .079
Endoleak 2 (2%)* N/A 2 (6%) –
*Total of three endoleaks in two patients; two type 1 endoleaks in one
patient.
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ment arms, several comments regarding perioperative out-
comes bear mentioning.
Like other investigators, we found that perioperative
outcome was impacted significantly with regard to opera-
tive time, ICU days, and length of stay in the ER group
(Table IV).1 However, overall postoperative morbidity rate
was not significantly reduced in the ER group (Table V). In
fact, it was slightly higher in the ER group and related to
the number of groin wound complications. The ER group
also needed a higher number of perioperative interventions
than did the TOR group. In addition, mortality rate was
not reduced in the ER group and actually trended higher
than in those patients treated with TOR at our center. We
report three deaths in the ER group (9%) versus 1 death in
the TOR group (1.5%); the 1.5% mortality rate for the
current TOR group is consistent with our 10-year mortality
rate of 1.2% for TOR before the use of ER. Of the three
perioperative deaths in the ER group, two were attributed
to sudden cardiac death and one to a hemorrhagic stroke in
a patient on warfarin sodium therapy. The single death in
the TOR group was attributed to gastrointestinal hemor-
rhage, sustained 60 days after surgery but while the patient
was still in our rehabilitation facility. Although the differ-
ence in perioperative mortality rate was not statistically
significant in the treatment arms, the trend is disturbing,
particularly given the similarities in preoperative medical
risk factors reported herein.
The results of our analysis leave us with questions as to
how ER can most beneficially be applied in our patient
population. Some investigators argue that ER offers earlier
return to functional status.1,27 Although we did not specif-
ically study that parameter, Aquino et al27 recently reported
on a prospectively conducted quality of life assessment for
patients receiving either ER or TOR. They concluded that
an earlier return to baseline function was detected in pa-
tients treated with ER versus those treated with TOR. On
closer examination of their data, however, these findings
are questionable. The groups were not randomized to the
two treatment arms and were clearly unmatched with re-
spect to aneurysm extent. Of the 51 patients enrolled in
their study, the 26 in the TOR arm were deemed unsuitable
for ER because of short proximal neck (n  10), pararenal
AAA (n  6), iliac aneurysm (n  8), or iliac occlusive
disease (n  1). The mere fact that the TOR group may
have needed suprarenal clamping or more extensive iliac
dissection, with their well-established higher risks of renal,
sexual, bladder, and bowel dysfunction, makes any conclu-
sions regarding postoperative quality of life in their two
treatment arms difficult to justify. Indeed, on long-term
follow-up, they report similar quality of life scores for the
two groups, suggesting that the short-term benefits do not
translate into a long-term advantage.
The reductions in operative time, ICU utilization, and
hospital stay that we observed certainly make ER more
attractive relative to TOR from a resource utilization stand-
point, but these reductions have not been shown to convey
a cost benefit when compared with TOR.28,29 In fact,
Sternbergh and Money30 found that ER offered a cost
disadvantage when compared with TOR and that Medicare
reimbursement did not cover the cost of ER because of the
current expense of the graft. Patel et al31 reported that ER
may be cost effective but only at medical centers where
TOR was performed with poor perioperative results. Al-
though we did not specifically address a cost-benefit analy-
sis in our series, if we applied the findings of Patel et al,31 it
can be inferred from the outcome data in our TOR group
that ER would not convey a cost advantage at our institu-
tion. In addition, the need for life-long imaging after ER
only adds to the cumulative cost. However, given the
reports of late rupture, proximal and distal attachment site
dilatation, endotension without detectable endoleak, and
other untoward sequelae, abandonment of a continued CT
or ultrasound scan follow-up protocol for the life of the
patient who undergoes ER would be unwise in our opin-
ion.
The shortcomings of ER not withstanding, the dura-
bility of the procedure, at least in the short and mid terms,
appears to be excellent in most cases.1,5,6,15,25 Although
our study did not focus on the long-term outcome of AAA
exclusion with ER, we did herein report two patients with
endoleaks needing intervention within the perioperative
period. One patient had two separate type 1 endoleaks and
another patient had a single type 1 endoleak, all of which
were treated in an endovascular fashion with resolution. In
addition, none of the 33 patients reported herein (or the
to-date total of 52 patients treated with ER at our institu-
tion) have had late rupture, aneurysm expansion, late en-
doleak, or graft migration develop, and none of the deaths
in the ER group were directly procedurally related. There
has been one late graft limb thrombosis, which was treated
endovascularly with good result. Indeed, the argument
could be made that we should be reporting equal outcomes
between the two groups, and in essence, we are. However,
given our relatively low morbidity and mortality rates with
TOR, we continue to believe that that procedure, at least at
our institution, conveys several advantages over ER for our
patient population. In treating patients with TOR, we do
not have to concern ourselves, or more importantly the
patients, with the possibility of the late causes of endograft
failure. In addition, the routine long-term imaging require-
ments are obviated. Most importantly, however, we offer
patients a relatively low-risk procedure with TOR.
We believe that the population most likely to benefit
from ER is the relatively poorly defined “high-risk” patient
group in whom the stress of TOR would be poorly toler-
ated. In that regard, the study by Salartash et al3 is partic-
ularly important. Their study showed that ER was associ-
ated with a marked reduction in parameters of the
postoperative stress response when compared with TOR.
Although their study group was relatively small, the find-
ings were compelling. The study was not, however, de-
signed to correlate the stress response with perioperative
outcomes, so it is unclear at this point as to how these data
apply to the AAA population as a whole. Although it may
be presumed that the patients undergoing TOR in our
study probably had a higher stress response than those
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undergoing ER, it did not result in poorer perioperative
outcomes.
One of the original goals of this study was to more
accurately define the high-risk AAA patient in whom ER
appeared to be clearly beneficial, but the preoperative med-
ical risk factor profiles in our two treatment arms were not
significantly different. Becker et al15 recently reported on a
large series of patients treated with ER, and analyzed out-
comes on the basis of a risk stratification system derived
from published reports on TOR. Although their overall
results appear to compare favorably with TOR at each risk
level, they did not compare ER with an ongoing or previ-
ously treated cohort of TOR subjects at their institution
with similar levels of risk. In a study designed to investigate
the outcomes of patients undergoing ER on the basis of a
retrospectively applied stratification of surgical risk, Bush et
al16 found similar rates of perioperative morbidity and
mortality in patients at both high and low risk undergoing
ER. In their conclusions, they advocated caution regarding
the use of ER for the otherwise ideal candidate for TOR.
We too have yet to define the patient population that will
derive maximal benefit from ER.
Several shortcomings of our study bear mentioning.
Clearly our study is relatively small and lacks the power of a
prospective, randomized, multiinstitutional trial. Also, it is
clear that our perioperative mortality rate is higher than has
been reported in other series.1,2,5,15,16,25,28 If that disturb-
ing trend continues as we accumulate a larger experience,
then certainly the entire issue of ER utilization at our
institution will have to be revisited. In addition, it may be
argued that the surgical outcomes from our early ER pro-
cedures cannot be compared with our well-established,
large TOR experience. However, we did not have the
learning-curve effect described by other investigators dur-
ing their early ER efforts.32,33 We have been able to achieve
a level of technical success similar to larger series in their
later phases of endograft deployment, with regards to graft
deployment, aneurysm exclusion, graft limb thrombosis,
open conversion, and direct procedure related mortali-
ty.1,5,6,15,25,33
The shortcomings of our study notwithstanding, it is
important to recognize that the impact of a specific therapy
on patient outcome is not always best measured with data
from large series but rather in the ability of the individual
surgeon to administer that therapy. Inasmuch as vascular
surgeons critique their stroke rate from carotid endarterec-
tomy or their ability to maintain primary, assisted primary,
or secondary patencies of infrainguinal bypass grafts, it is
imperative that the same be done with regard to this new
technology as it applies to the treatment of AAA. It is
important to recognize that most reports regarding ER
come from large centers with extensive endovascular expe-
rience. Many of these centers have participated in the
development of and clinical trials evaluating these endovas-
cular devices. As more and more vascular surgeons use ER
for the treatment of their patients, it is essential that they
analyze their results in an objective fashion to assess the
impact, or lack thereof, of ER on their patient populations.
CONCLUSION
With the exception of preoperative pulmonary comor-
bidity, we detected minimal differences among the preop-
erative medical risk factors of patients undergoing ER as
opposed to TOR at our institution. ER was associated with
significant decreases in operative time, ICU stay, and over-
all length of stay, relative to TOR. However, ER was
associated with similar rates of significant perioperative
morbidity and mortality when compared with TOR, and
none of the mortalities in the ER group could be attributed
to pulmonary causes. These results suggest that ER offers
improvements in hospital convalescent and operating room
times but no beneficial impact on overall morbidity and
mortality rates when similar preoperative medical risks ex-
ist, especially when used at medical centers where low
morbidity and mortality rates are already established for
TOR. The definition of the high-risk patient that may
benefit from ER to the greatest degree remains imprecisely
defined. Other centers performing ER should undertake
such an analysis to assess its impact on their patients.
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DISCUSSION
Dr Samuel R. Money (New Orleans, La). I would like to
thank the authors for sending me a copy of their manuscript. I
know everybody says this, but it truly is a pleasure to read a
manuscript that is as well prepared as this one was and also receive
it in a timely fashion rather than the night before. So, I want to
thank you for e-mailing it to me a few weeks in advance of the
meeting. I really do appreciate that.
I think the authors should be commended for many reasons.
Firstly, over an 18-month period they performed almost 200 aortic
aneurysm operations. Of these, less than 50%, only 99, were truly
elective infrarenal aneurysm repairs. A fair majority were thoraco-
abdominal aneurysms or visceral reconstructions or required ur-
gent or emergent surgery. This is the aortic practice that a lot of us
dream of. I know some of us may have nightmares about this kind
of practice, but this is really the kind of practice that people dream
of having and I think you folks have it.
The contention of their paper is that endovascular repair may
offer some improvements in hospital convalescence but no true
beneficial impact long term on morbidity or mortality. There is one
significant difference in the preoperative risk factors, and that was
pulmonary disease. This leads to my first question. Would the
patients who had the severe pulmonary disease, and it was worse in
the endo group, if these patients had been amenable to open
surgical repair, would this have changed your long-term results,
increased your already significantly longer hospital stay, and also
increased your rate of complications?
The second question is on deaths, and after hearing the
presentation, I believe it probably is not to be belabored; however,
you had 3 deaths in the endo group. That is approximately a 9% to
10% mortality. Most of us do not see anything like that; however,
none of the deaths I think were truly related to the procedure.
Were these patients extremely sicker than the open patients?
The other thing is your open death rate. Despite happening at
postop day 60, was it procedure-related, as this patient was still on
the rehabilitation unit in your hospital following an aneurysm
repair?
However, I think the real question that this paper opens up is
the larger picture that must be addressed: do we trade in a tradi-
tional standard operation with very good results for one that may
not be as durable, may require secondary procedures, but in all
honesty we know has a significantly less metabolic effect on the
patient? Let me put it another way. If you have a hospital stay in
your open group of approximately 11 days versus a hospital stay in
the endovascular group of 2 days, is it reasonable to say that we are
going to treat patients in an endovascular fashion and accept the
fact that some will come in for multiple small repeat procedures in
the future? Over 80% of our secondary procedures following
endovascular repair are done in a 24-hour or less length of stay.
Isn’t it worth it to tell someone that instead of spending 11 days in
the hospital now they can spend 2 days in the hospital now and
maybe spend another 1 or 2 days over the next 5 or 10 years? I
think the trade-off is something that must be individualized, and I
am curious what the authors think about that.
I believe this paper described results using an endovascular
graft that one of the two best that we have on the market today.
However, that is today. New generation devices are coming, and
they will probably reduce some of the complications and also
facilitate the care of these patients. I think that technology will
continue to grow, and I am certain that some of the problems with
endoleaks, migrations, and limb occlusion will be minimized over
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the next 5 to 10 years as new generations of devices are developed.
I would like to hear what the authors feel about that.
Thank you for sending me the paper. I appreciate commenting
on it.
Dr John Ligush, Jr. Thanks, Sam, for taking the time to
comment on it, and thanks for the questions. I do not think I can
address them in order. I am going to try to just work my way
through them as I think through this.
As my thought process on endovascular AAA has evolved, I
have gone through several phases. The first was “endo-fascination,”
and that quickly turned to “endo-infatuation” and then “endo-
panic,” thinking I am the only one not doing this because I am not
part of a trial. Then we started doing them, and there was “endo-
love” because this is truly fascinating technology and the technical
challenges are certainly present. Now I am back to an “endo-
reality” state because as a vascular surgeon who does endovascular
surgery, I am not looking for ways to exploit this technology or
broadly apply it. I am looking for the best way to treat my patients,
as I am sure we all are. The truth is that we do a good job with open
repair, and that sets a high standard for any other AAA repair
procedure. I believe that this therapy, like you said, has to be
individualized, but we have some serious unanswered questions
regarding this therapy and I applaud all of the authors who have
presented here and those who present nationally who try to look at
this in a scientific fashion and try to answer those questions.
The truth is we individualize our therapy. We do discuss it
with every patient who is a candidate in an informed consent
fashion, and we go over the risks and the shortcomings very carefully.
We look at ways to have this therapy dove tail with our open aneurysm
experience, because I believe this really does come down to a mortal-
ity, morbidity, and complete aneurysm exclusion issue.
I think the length of stay issue is a significant one, and our
paper was probably not presented in the most appropriate fashion.
We presented mean length of stay. The median length of stay for
endovascular aneurysm repair was 1 day; the median length of stay
for open repair was 5 days. We had some significant outliers that
stayed in the hospital for a long period of time and skewed our
open data. Nonetheless, it still statistically significantly favors en-
dovascular repair. If the length of stay issue becomes the major
point of contention, it really comes down to a cost-benefit analysis,
and your group clearly showed that there was not a cost-benefit
advantage when endovascular repair was compared to open repair;
in fact, there was a disadvantage with endovascular repair. So then
we could get into quality of life issues, and I think we would all
agree that these patients clearly look better on postop day 1 when
compared to our open aneurysm repair patients. However, when
you look at longitudinal quality of life studies, I think Aquino’s
study recently published in the Journal of Endovascular Therapy is
an important one. While they showed that there was an early
quality of life advantage with endovascular repair, at 6 months it
basically equalized between open and endovascular repair. I think
the cost issue and the quality of life issue are a wash. I guess the
answer to your question is, no, we do not broadly apply this
technology and we individualize it.
Regarding the pulmonary morbidity question, I think you are
right. This is a very difficult patient population to treat, and we are
continually challenged by this patient population. In our study, of
the patients with significant pulmonary morbidity in the endovas-
cular group, there was one patient that was on home O2 and
steroids with an FEV1 of less than 1. I believe his operative risk
would have been very high from an open standpoint, so I think the
answer to your question is that that patient probably would not have
received open aneurysm repair. I would have to go back and specifi-
cally look at that patient again. However, the other patients, I believe,
would have qualified for open repair, and if you really look back at our
10-year mortality ıgures at our institution, we had a 1.2% mortality
before we started doing endovascular repair. So, we have treated a lot
of patients with significant pulmonary morbidity, but I cannot tell you
how many were excluded from open repair during that 10-year
period. I do not think that data can be extracted.
I think the whole issue comes down to a risk stratification
scenario, in that we do not really understand, and I do not really
know how to stratify these patients. We know how to stratify them
based on ASA classification, but we do not know how to apply this
technology based on that stratification. Without a randomized trial
comparing patients at varying levels of operative risk, we are not
going to have that data.
Regarding the deaths in our study, I think the answer to that
question is that we had 3 deaths. I think they are all perioperative
deaths, so I am not exactly sure how to answer your questions. A
direct procedurally related cause, I believe, would be something
that happened right in the operating room, either related to the
endograft placement or the aneurysm repair. The one patient that
died in our open group probably would not have been included in
most series. The patient was 60 days postop and in a rehab facility
that adjoins our hospital, but these are all perioperative deaths.
As regards the new technology, I will share with you what Bob
Rutherford told me: never bet against technology. I think this is a
treatment that is going to continue to improve. We are going to
find ways to treat graft migration, fixation problems, proximal
aneurysmal dilatation, and I think suprarenal fixation is going to
have an impact in treating patients with these grafts. I think some
of these problems are going to be solved and some will remain
unsolved, and I look forward to this developing technology.
Dr Mark E. Sesto (Weston, Fla). I have adapted as others to
minimally invasive surgery, although I must admit my heart is still
with maximally invasive surgery, and as I hear the presentations
that compare endograft repair of aneurysms with open repair, I am
wondering if open repair is being fairly represented. Most are from
large institutions or clinics that are training fellows and residents
and medical students, and I am always enamored that the operative
times, the blood losses, and the hospital stays seem longer than
what we are used to without training residents. With infrarenal
abdominal aortic aneurysm elective repair, our operative times are
around 2 hours, our blood loss is less than a unit, and our hospital
stay is about 4 days. We all know that good results are patient
selection, but intraoperatively it is a deliberate quick operation,
technical precision, and minimal blood loss. Do you feel that, in
your opinion, in some of these large studies that the training of
resident is effecting the results that are reported with open repair?
Dr Ligush. I think all of your points are valid. I do believe
that resident/fellow training impacts operative time and blood
loss, but many of these open patients had extensive iliac involve-
ment with their AAA. I can only speak for our institution and our
experience, and I believe that our operative times are longer and
our blood loss is higher than your experience, but our periopera-
tive outcomes are very good. I think that the management of the
patient in the preoperative and postoperative period is the key at
our institution, treating them with perioperative beta blockade or
whatever means you have to decrease their cardiac morbidity, and
that is where our residents and fellows have a positive impact. I
believe that the answer lies in the perioperative period, perhaps
more so than the intraoperative.
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